Clinical Scorecard: Video: Letting Nature Lead – with John Maher
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Video |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Not described in the source. |
| Care Setting | Maher’s career combines academic research, clinical practice, and cell-therapy development through Leucid Bio. |
Key Highlights
- John Maher is a clinical immunologist, Scientific Founder and Chief Scientific Officer of Leucid Bio.
- He leads the CAR Mechanics research group at King’s College London.
- His work in CAR T-cell immunotherapy spans more than two decades, with a particular focus on developing treatments for solid tumors.
- While working in Michel Sadelain’s laboratory at Memorial Sloan Kettering Cancer Center, Maher helped develop second-generation CAR technology incorporating CD28; the approach subsequently achieved clinical success in blood cancers.
- The interview covers his route into immunology, contributions to CAR T development, and the scientific thinking behind his current research.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The source describes Maher’s work in CAR T-cell immunotherapy, particularly development of treatments for solid tumors; it does not specify a patient population.
The source describes his contribution to second-generation CAR technology incorporating CD28 and his current research, but gives no treatment protocol details.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.